The federal indictment alleges that Michael McMillan used a group of affiliated Nevada companies to recruit medical providers, distribute skin substitutes, coordinate reimbursement-dependent invoices, compensate sales representatives, and manage the disputed flow of government healthcare payments
WASHINGTON, DC — Federal prosecutors say Protectus LLC and five related Nevada companies supplied the organizational machinery behind an alleged wound-care operation that caused Medicare, TRICARE, and CHAMPVA to pay approximately $268 million on disputed skin-substitute claims.
The government alleges that Michael McMillan owned and controlled the affiliated businesses, collectively described in the indictment as Protectus, while using their commercial relationships to recruit providers, deliver products, support billing activity, divide reimbursements, and compensate commissioned sales representatives.
Prosecutors contend that participating medical practices paid nothing before receiving skin substitutes, owed Protectus nothing when government programs denied reimbursement, and surrendered only sixty to seventy percent when claims succeeded, leaving substantial proceeds with the practices.
That retained thirty-to-forty-percent share allegedly guaranteed providers thousands of dollars from every reimbursed claim, creating what prosecutors characterize as illegal remuneration hidden within business terms described through invoices, rebates, discounts, credits, contracts, and contingent payment arrangements.
McMillan has not been convicted; the companies generally discussed as Protectus are not separately named defendants in the public case caption, and every allegation concerning their activities, finances, employees, and relationships remains subject to evidentiary testing.
Six Nevada Companies Form the Alleged Protectus Network
The federal indictment against Michael McMillan identifies Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC as affiliated Nevada limited-liability companies owned and controlled by McMillan.
Although the charging document lists six legal entities, it ordinarily uses the collective term Protectus when describing product distribution, provider recruitment, billing assistance, reimbursement collection, invoice preparation, representative compensation, and the alleged payment of provider kickbacks.
That drafting choice presents a coherent prosecution narrative, but it also leaves transaction-level questions concerning which company signed each agreement, employed each worker, maintained each account, shipped each product, issued each invoice, or received each payment.
Those distinctions could become important during discovery because corporate records may show separate personnel, bank accounts, customer arrangements, tax treatment, inventory responsibilities, or approval procedures even where prosecutors allege common control and coordinated participation.
Protectus LLC Was the Publicly Identified Hub
Federal announcements describe McMillan as the owner of Protectus LLC and related entities, positioning the namesake company as the recognizable center of an alleged network whose operations extended across several companies, provider practices, and government healthcare programs.
The indictment’s broader collective usage nevertheless avoids claiming that Protectus LLC alone performed every challenged act, meaning responsible reporting should not automatically attribute each email, invoice, commission, shipment, claim entry, or receipt to that specific company.
Prosecutors may attempt to demonstrate centralized control through ownership documents, internal communications, accounting systems, approval chains, shared employees, intercompany transfers, and McMillan’s alleged personal involvement with provider terms and representative compensation throughout the charged period.
Defense counsel may respond that ownership and coordination are ordinary features of affiliated businesses, requiring the government to prove criminal knowledge and participation instead of asking jurors to infer illegality merely from a recognizable corporate family.
Recruitment Allegedly Expanded the Provider Network
According to prosecutors, McMillan and Protectus hired sales representatives to recruit physicians, podiatrists, nurse practitioners, and other medical providers who could order, apply, and bill government programs for costly skin substitutes used during wound-care treatment.
The representatives allegedly explained that participating practices could retain a predetermined share of successful reimbursements, making provider profitability a central recruitment feature rather than an incidental margin arising independently after an ordinary product purchase.
Prosecutors identify anonymized representatives and providers located in Texas, California, and Utah, while alleging conduct within the Northern District of Texas and elsewhere that connected geographically dispersed practices with the Nevada-based Protectus organization.
The defense may distinguish lawful product marketing from prohibited referral activity, arguing that representatives performed genuine commercial services while licensed clinicians retained independent responsibility for patient selection, medical necessity, treatment decisions, documentation, and final billing submissions.
Products Allegedly Arrived Without Upfront Payment
The government says Protectus offered skin substitutes without requiring providers to purchase inventory before treatment, reducing the immediate financial exposure normally associated with ordering expensive medical products whose reimbursement could later be delayed, reduced, audited, or denied.
If a government program rejected the corresponding claim, the practice allegedly owed Protectus nothing for the supplied product, while successful reimbursement triggered an invoice calculated from the amount collected rather than a fixed price paid before application.
Prosecutors portray this denial protection as part of an inducement because providers allegedly faced little product-cost risk while preserving a substantial percentage of every successful claim, creating an unusually favorable economic opportunity connected directly with government payment.
The defense can characterize the same structure as consignment, extended credit, risk allocation, contingent invoicing, or customer accommodation, making intent, disclosure, program rules, commercial context, and actual contract language central to any eventual trial.
Invoices Allegedly Divided Successful Reimbursements
Once Medicare or another government program paid a claim, Protectus allegedly invoiced the provider for approximately sixty to seventy percent of the reimbursement, while explicitly or effectively allowing the medical practice to retain the remaining thirty to forty percent.
One invoice described by prosecutors recorded total collections of $53,625.60, stated that a provider would keep $16,087.68, and listed $37,537.92 as due to Protectus Technologies, illustrating the alleged division through ordinary accounting documentation.
That example matters because it connects one specifically identified affiliate with a concrete transaction, while also showing how prosecutors may translate a complicated reimbursement theory into a straightforward sequence involving payment, retention, invoicing, and remittance.
An invoice alone does not establish a kickback, however, because prosecutors must demonstrate that the retained value was knowingly and willfully offered to induce federally reimbursable purchases, orders, arrangements, or recommendations rather than serving a lawful commercial purpose.
Contracts Allegedly Guaranteed Provider Profit
The indictment describes a July 2023 email concerning a Texas provider whose employee allegedly reported that a new contract promised forty-percent profit, although an invoice appeared to reflect the previous thirty-five-percent arrangement used within the Protectus relationship.
McMillan allegedly forwarded that message to a Protectus employee and directed that the discrepancy be corrected, an exchange prosecutors may use to argue that provider profit was contractually designed, monitored, and approved at the organization’s highest level.
The defense may seek the complete contract, amendment history, surrounding correspondence, accounting definitions, product pricing, and subsequent reconciliation to argue that the word profit described a lawful negotiated discount rather than corrupt remuneration.
Jurors may therefore confront competing interpretations of familiar business records, with prosecutors emphasizing economic substance and inducement while defense lawyers emphasize written terms, industry practice, regulatory ambiguity, professional reliance, and legitimate value delivered.
Protectus Allegedly Managed a Reimbursement-Dependent Stream
The alleged payment stream began with product delivery and treatment, continued through a provider’s claim to a government program, moved into a medical practice after reimbursement, and reached Protectus only after a percentage-based invoice became payable.
From Protectus receipts, prosecutors say the organization covered business expenses, compensated sales representatives, moved funds through corporate accounts, and supported transactions that later became subjects of criminally derived property counts and requested forfeiture remedies.
This sequence explains why the companies occupy a central position within the indictment, because the alleged structure required coordination among inventory, provider onboarding, billing support, reimbursement monitoring, invoicing, collection, representative reporting, accounting, and financial approvals.
It also creates multiple attribution questions because employees performing clerical functions may not share the knowledge attributed to executives, representatives may understand compensation differently, and individual providers may possess distinct information about claims and pricing.
The $268 Million Figure Describes Program Payments
Prosecutors allege that Medicare, TRICARE, and CHAMPVA paid approximately $268 million on challenged skin-substitute claims, with Protectus companies receiving approximately $174 million and participating medical providers retaining approximately $94 million under the disputed arrangements.
Those figures represent the government’s proposed division of one overall payment total, meaning the provider share and Protectus share should not be added again to create an inaccurately inflated loss exceeding the approximately $268 million already alleged.
The indictment separately alleges approximately $27 million in reimbursement-linked payments to sales representatives, but those commissions allegedly came from Protectus receipts and likewise should not be treated as additional government disbursements above the headline amount.
Final loss calculations may differ substantially from public allegations because courts can examine claim eligibility, legitimate medical value, pricing representations, kickback consequences, repayments, denials, credits, supported treatment, and evidentiary limits affecting individual transactions.
Claim Assistance Allegedly Extended Beyond Product Distribution
The government alleges that McMillan and Protectus submitted claims for providers or helped them prepare submissions, expanding the companies’ alleged role from product supplier into the administrative processes through which government programs evaluated and paid reimbursement requests.
That alleged assistance could allow prosecutors to connect internal Protectus personnel with claim information, invoice terms, acquisition-price representations, provider communications, reimbursement timing, and knowledge about the economic arrangements existing behind submitted billing fields.
The defense may argue that billing assistance was ministerial, based upon information furnished by providers or outside specialists, while final submission authority and clinical documentation remained with independently licensed practices responsible for their own representations.
Determining responsibility will require more than identifying who accessed software, because investigators and jurors may need to examine user credentials, submission timestamps, correction histories, written instructions, supervisory approval, training, and communications surrounding representative claims.
Box 19 Connects Corporate Economics with Alleged Fraud
Prosecutors say relevant Medicare claims required providers to disclose actual acquisition prices after accounting for discounts, rebates, refunds, and other adjustments within Box 19, making the final economic cost of each skin substitute important to reimbursement.
The indictment alleges that McMillan and Protectus reported, assisted, or counseled the reporting of inflated acquisition prices that did not reflect what providers ultimately owed after reimbursement-contingent invoices and percentage retention were considered.
Under the government’s theory, the same retained percentage characterized as an illegal kickback also helps demonstrate why the claimed acquisition price was misleading, joining the alleged remuneration arrangement with the healthcare-fraud conspiracy through corporate billing activity.
Defense lawyers may contest whether guidance clearly addressed these arrangements, whether invoice timing changed the reportable amount, whether later adjustments required updates, and whether McMillan knowingly controlled any materially inaccurate statement submitted to a payer.
Refunds Allegedly Followed Changes in Claim Status
The indictment describes a California provider that reportedly returned payments on two claims to Medicare and requested reimbursement of related Protectus product invoices until the claims could be rebilled through another business associated with the provider.
McMillan allegedly indicated that Protectus would handle the matter, after which an employee reportedly processed a refund through the accounting system, providing prosecutors with another example of product obligations changing alongside reimbursement status.
The government may argue that this exchange demonstrates how Protectus absorbed claim-denial or repayment risk while preserving provider gains after successful billing, reinforcing its description of a coordinated inducement rather than a conventional completed sale.
The defense may answer that reversing an invoice following repayment was responsible bookkeeping, protected a customer from paying for rescinded revenue, and demonstrated transparent reconciliation rather than consciousness of any healthcare or kickback offense.
Sales Representatives Allegedly Received $27 Million
Prosecutors allege that Protectus representatives received approximately $27 million in compensation tied to reimbursements generated by medical practices they recruited, creating a second incentive layer alongside the percentage of proceeds retained by participating providers.
Representative commissions allegedly became payable only after a government program reimbursed the relevant practice and Protectus collected its invoice, linking recruiter compensation with successful claims, provider remittances, and internal commission reports reviewed within the organization.
The government may use monthly reports, emails, checks, wires, provider account histories, and McMillan’s alleged approvals to show that Protectus systematically tracked revenue from recruited practices before releasing corresponding compensation to individual representatives.
Commission-based sales compensation is common within legitimate commerce, so prosecutors must establish the required unlawful purpose while the defense can argue that payments rewarded bona fide marketing, account support, product education, or other documented services.
Different Protectus Participants May Have Different Knowledge
The collective label Protectus can simplify a lengthy indictment, yet criminal liability remains individualized because an owner, executive, accountant, billing assistant, warehouse employee, sales representative, and contracted provider may understand the same transaction in fundamentally different ways.
An employee preparing an invoice may know only an approved percentage, while a representative may focus upon customer development and a provider may rely upon separate billing advice, creating factual differences that broad organizational language can obscure.
Prosecutors may attempt to prove shared knowledge through training materials, recurring calculations, compliance warnings, internal discussions, claim instructions, reimbursement reports, and repeated approvals that allegedly made the organization’s purpose visible across functional roles.
Defense counsel will likely resist any assumption that corporate association establishes conspiratorial agreement, demanding evidence showing that particular individuals understood the alleged falsity or inducement and knowingly chose to advance a charged criminal objective.
Three Government Programs Were Allegedly Affected
Medicare supplied the dominant reimbursement stream described publicly, but the indictment also identifies TRICARE and CHAMPVA, bringing programs serving military personnel, retirees, veterans, survivors, and eligible family members within the alleged Protectus payment structure.
That multi-program allegation helps explain why investigators included the Federal Bureau of Investigation, Health and Human Services Office of Inspector General, Defense Criminal Investigative Service, and Department of Veterans Affairs Office of Inspector General.
Each program may apply distinct coverage rules, contractors, forms, pricing instructions, audit procedures, and payment systems, requiring prosecutors to prove how challenged Protectus conduct affected particular claims rather than relying upon one generalized reimbursement narrative.
The defense may use those administrative differences to challenge materiality, notice, causation, and knowledge, especially when the same product, provider arrangement, or billing assistance received different treatment across government healthcare programs during the charged period.
The Charges Target McMillan Rather Than the LLCs Separately
Count One charges McMillan with conspiracy to commit healthcare fraud, Count Two charges a separate conspiracy to defraud the United States and pay healthcare kickbacks, and Counts Three through Nine concern monetary transactions involving allegedly criminally derived property.
The six Protectus companies are described throughout the charging narrative, but McMillan is the individual defendant named in the case caption, making careful language necessary when discussing what the organizations allegedly did and what has actually been charged.
Corporate records can still become essential evidence even without separate company defendants, because prosecutors may use accounts, contracts, invoices, payroll, tax records, ownership documents, and communications to establish McMillan’s alleged control, knowledge, agreement, and proceeds.
Conversely, the absence of a separately charged entity does not establish corporate innocence or wrongdoing, because charging decisions may reflect prosecutorial strategy, available remedies, cooperation, evidentiary judgments, or practical considerations not explained within an indictment.
Affiliated Companies Do Not Erase Corporate Separateness
Common ownership can support a prosecution theory of coordinated control, but affiliated limited-liability companies generally remain distinct legal organizations whose assets, contracts, employees, creditors, and obligations cannot automatically be collapsed merely because one individual controlled them.
Prosecutors may seek to trace money across related accounts and show that formal boundaries did not change the alleged scheme’s substance, while defense counsel may insist upon entity-specific proof for every receipt, instruction, transfer, invoice, and purchase.
Third parties such as lenders, vendors, employees, landlords, investors, spouses, or co-owners may also assert legitimate interests that differ sharply from McMillan’s position, particularly when property restraints or forfeiture demands reach assets associated with corporate funds.
Courts may therefore closely examine beneficial ownership, authorized signatories, transfer purposes, commingling, capitalization, accounting treatment, legitimate revenue, and documentary consistency before determining whether particular property can properly be attributed to charged unlawful activity.
Financial Tracing Will Test the Corporate Narrative
The seven transactional counts allege purchases exceeding $10,000 involving property derived from the two charged conspiracies, including payments connected with real estate, luxury vehicles, and a private aircraft acquired during the alleged scheme.
Unlike concealment-focused laundering allegations, the cited transactional statute principally requires qualifying monetary transactions in criminally derived property, together with proof that McMillan knew the funds represented proceeds from some form of criminal activity.
Prosecutors will likely trace provider reimbursements into Protectus accounts, follow invoices and corporate transfers, separate operating expenses from distributions, and connect particular funds with the later property purchases identified as allegedly unlawful transactions.
The defense can identify loans, investments, earlier balances, legitimate product revenue, financing, asset sales, or competing tracing methodologies, arguing that corporate accounts containing mixed funds do not make every later expenditure criminally derived.
Seizure Does Not Equal Permanent Forfeiture
Federal authorities reported assets valued at approximately $35 million seized in connection with McMillan’s case, while the indictment separately identifies property interests and seeks forfeiture remedies that would require further legal proceedings and judicial findings.
Pretrial seizure preserves disputed property while litigation continues, whereas permanent criminal forfeiture ordinarily depends upon convictions, statutory connections, tracing evidence, procedural compliance, and resolution of valid ownership claims presented by affected third parties.
The announced figure should therefore not be described as money already recovered for Medicare, TRICARE, or CHAMPVA, because restitution, forfeiture, seizure valuation, gross proceeds, provider retention, corporate receipts, and program loss measure different things.
McMillan and other claimants may dispute probable cause, ownership, valuation, legitimate funding, commingling, substitute-property requirements, or lien priority, ensuring that substantial financial remedies can remain contested even after substantive criminal allegations are resolved.
The Regional Takedown Magnified the Protectus Allegations
An NBC 5 Dallas-Fort Worth report on the North Texas enforcement action prominently placed McMillan’s case among seven regional prosecutions involving thirteen defendants and more than $365 million in collectively alleged fraudulent billing.
Because the approximately $268 million Protectus allegation represented the largest individually announced figure within that regional group, the company names, private aircraft, luxury vehicles, expensive properties, and provider-payment claims received immediate public attention.
National and regional totals can demonstrate enforcement scale, yet unrelated accusations involving laboratories, hospices, neurological testing, equipment suppliers, or other defendants cannot establish McMillan’s intent, the Protectus companies’ conduct, or any disputed claim.
Courts must keep the evidence rigorously individualized, ensuring that campaign-wide statistics, vulnerable-patient narratives, and conspicuous property descriptions do not substitute for proof directly connecting McMillan with each alleged agreement, representation, payment, and transaction.
Corporate Compliance Lessons Extend Beyond Protectus
Healthcare distributors should closely examine arrangements where providers pay nothing upfront, owe nothing after denial, retain fixed percentages of successful reimbursement, and receive billing assistance from the same organization supplying the reimbursed medical product.
Companies should separately review representative compensation that becomes payable only after recruited providers obtain government reimbursement, especially when commissions are calculated from collected claims and marketing materials emphasize predictable provider profit rather than documented clinical value.
Compliance teams should preserve entity-specific contracts, invoices, claim instructions, shipping records, commission reports, bank statements, access logs, refund communications, training materials, legal advice, and approval histories that can reconstruct both economic substance and individual knowledge.
Independent compliance sampling should compare actual acquisition-price disclosures against final economic obligations after discounts, rebates, refunds, credits, contingencies, and provider retention, while also testing whether treatment selection remained appropriately insulated from commercial incentives.
Affiliated companies should document intercompany services and transfers with particular care, because collective branding may be convenient operationally but can later make it difficult to identify which organization performed, approved, benefited from, or corrected a questioned activity.
Public Allegations Create Immediate Reputation Pressure
An indictment linking six affiliated companies with a $268 million healthcare allegation can rapidly transform ordinary corporate names, employee titles, invoices, contracts, and customer relationships into search results implying misconduct before courtroom testing establishes individual facts.
Organizations facing that imbalance may require disciplined crisis public-relations management that distinguishes allegations from adjudicated findings, coordinates authorized statements with counsel, protects confidential information, and corrects demonstrable errors without obstructing legitimate reporting or investigation.
Longer-term reputation-rebuilding strategies can carefully document verified compliance improvements, independent reviews, leadership decisions, procedural developments, and final outcomes without concealing material facts or inaccurately portraying an unresolved federal prosecution as complete institutional exoneration.
McMillan, Protectus entities, employees, sales representatives, medical providers, creditors, and property claimants may occupy sharply different positions, making one collective response potentially misleading when evidence, legal exposure, and access to relevant records vary substantially.
Responsible communications should preserve the presumption of innocence while avoiding categorical claims unsupported by documents, because premature explanations can conflict with later court filings, waive strategic protections, or unfairly implicate uncharged individuals and businesses.
What Happens Next in the Protectus Case
Pretrial proceedings may examine corporate ownership, entity-specific bank records, provider agreements, product invoices, reimbursement data, claim submissions, accounting access, sales compensation, electronic communications, search procedures, seized assets, witnesses, and expert interpretations of billing requirements.
Prosecutors will attempt to show that McMillan used the Protectus network as an integrated system for recruiting providers, managing reimbursement-linked remuneration, supporting misleading claims, collecting government proceeds, compensating representatives, and funding later property transactions.
The defense will seek to separate lawful distribution, credit, marketing, accounting, and administrative activities from alleged criminal agreements, while challenging whether collective references to Protectus reliably establish McMillan’s knowledge or responsibility for individual acts.
Expert testimony may become important when jurors evaluate skin-substitute reimbursement, acquisition-price disclosure, discounts, rebates, contingent invoices, corporate accounting, representative commissions, medical value, claim materiality, and accepted practices within a rapidly changing wound-care market.
Any plea, trial, forfeiture judgment, restitution order, or sentence would depend upon sustained counts and proven facts, not solely upon the indictment’s corporate narrative, extraordinary payment totals, publicly described assets, or national enforcement context.
Until jurors return verdicts or another lawful resolution concludes the prosecution, McMillan remains presumed innocent, every allegation involving Protectus LLC and its related entities remains disputed, and the government retains the burden of proving each charged offense beyond a reasonable doubt.
